GREM1/FGFR1-activated myofibroblasts induce immunosuppression and accelerate metastasis in high-grade serous ovarian cancer
Proceedings of the National Academy of Sciences · 16.06.2026 · 123 (24)
DOI: 10.1073/pnas.2529786123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 10.06.2026. Verfasst von Runrong Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Myofibroblasts, Intercellular Signaling Peptides and Proteins, Cystadenocarcinoma, Serous. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Key Research and Development Program of China (NKPs).
Abstract (Originalsprache)
Joint effect of cancer-associated fibroblasts (CAFs) and regulatory T cells (Tregs) can drive immunosuppression in high-grade serous ovarian cancer (HGSOC), thereby promoting tumor metastasis and limiting the clinical benefit of PD-1/PD-L1 blockade. However, the mechanistic crosstalk between CAFs and Tregs remains unclear. By integrating bulk RNA-seq, single-cell RNA-seq datasets, and spatial transcriptomics datasets with functional assays, we identified a population of TGF-β1-driven Gremlin1 (GREM1) + myofibroblastic CAFs (myCAFs) enriched in HGSOC metastatic lesions. These GREM1 + myCAFs activated the FGFR1-MAPKs-NFκB-TDO2-kynurenine axis via autocrine signaling, promoting tumor growth, metastasis, and immune evasion characterized by the infiltration of CD4 + Tregs and dysfunctional CD8 + T cells. GREM1 knockdown suppressed tumor metastasis, restored antitumor T cells response, remodeled CAF subtype composition and potentiated anti-PD-1 therapy efficacy. This study highlights the pro-metastatic role of GREM1 + myCAFs across multiple tumors and provides a rationale for combining anti-PD-1 therapy for metastatic HGSOC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, China.
- Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, Southern Medical University, Guangzhou 510515, China.
- The First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China.
- Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
ORCID-Profile: Yue Chen, Yunshan Ning
Förderung
- MOST | National Key Research and Development Program of China (NKPs)
Zitieren
APA
Li, R., Huang, X., Chen, Y., Chen, X., Yang, Y., Liu, Y., Bai, B., Meng, F., Li, Y., & Ning, Y. (2026). GREM1/FGFR1-activated myofibroblasts induce immunosuppression and accelerate metastasis in high-grade serous ovarian cancer. Proceedings of the National Academy of Sciences, 123(24). https://doi.org/10.1073/pnas.2529786123
Vancouver
Li R, Huang X, Chen Y, Chen X, Yang Y, Liu Y, et al. GREM1/FGFR1-activated myofibroblasts induce immunosuppression and accelerate metastasis in high-grade serous ovarian cancer. Proceedings of the National Academy of Sciences. 2026;123(24). doi:10.1073/pnas.2529786123
BibTeX
@article{Li2026,
author = {Li, Runrong and Huang, Xizhan and Chen, Yue and Chen, Xiaowen and Yang, Yue and Liu, Yurui and Bai, Binyi and Meng, Fanliang and Li, Yan and Ning, Yunshan},
title = {GREM1/FGFR1-activated myofibroblasts induce immunosuppression and accelerate metastasis in high-grade serous ovarian cancer},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {24},
doi = {10.1073/pnas.2529786123}
}
EUVIMED